日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

一项针对晚期胰腺癌或结直肠癌患者的BMS-813160(一种CCR2/5双重拮抗剂)联合化疗或纳武利尤单抗的1b/2期研究

Le, Dung T; Folprecht, Gunnar; Varghese, Anna M; Gutierrez, Martin; Noel, Marcus; Trikalinos, Nikolaos A; Chen, Eric; Dayyani, Farshid; Davis, S Lindsey; Ma, Wen Wee; BasuMallick, Atrayee; Garrido-Laguna, Ignacio; Osawa, Mayu; O'Brien, Shaun; Novosiadly, Ruslan D; Xu, Ke; Greenawalt, Danielle M; Dutta, Santanu; Twyman Saint Victor, Christina; Lenz, Heinz-Josef

Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses

胰腺癌联合免疫疗法的细胞计量图谱:基于血液的特征揭示疫苗和检查点抑制剂的反应

Sidiropoulos, Dimitrios N; Zhang, Zhehao; Durham, Jennifer N; Charmsaz, Soren; Gross, Nicole E; Lee, Jae W; Sun, Yanyi; Perikala, Susheel; Tandurella, Joseph A; Lvovs, Dmitrijs; Mitschang, Arik; Lemson, Gerard; Shin, Sarah M; Hernandez, Alexei G; Mitchell, Sarah; Leatherman, James M; Danilova, Ludmila; Wang, Hao; Fertig, Elana J; Jaffee, Elizabeth M; Bever, Katherine M; Le, Dung T; Ho, Won Jin

A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.

一项随机 II 期研究:CRS207/GVAX 联合抗 PD-1 和抗 CTLA4 可将间皮素和 mKRAS 特异性 T 细胞募集到 PDAC 中。

Bever Katherine M, Huff Amanda L, Danilova Ludmila, Wetzel Meredith, Tandurella Joseph A, Durham Jennifer N, Wang Tingchang, Lee Jae W, Coyne Erin M, Montagne Janelle M, Mitchell Jacob T, Hernandez Alexei G, Shin Sarah M, Anders Robert A, Wang Hao, Fertig Elana J, Jaffee Elizabeth M, Le Dung T, Ho Won Jin

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer

纳武利尤单抗和瑞拉利单抗用于治疗不可切除或转移性错配修复功能正常的结直肠癌患者

Christenson, Eric S; Ho, Won Jin; Shu, Daniel; Durham, Jennifer N; Brancati, Madelena; Davis Bruning, Heather; Petrie, Susan; Wang, Hao; Lu, Jiayun; Bever, Katherine M; Laheru, Daniel; de Jesus-Acosta, Ana; Browner, Ilene; Donehower, Ross; Pishvaian, Michael J; Azad, Nilofer; Zhu, Qingfeng; Valentin, Alens; Suresh Babu, Jayalaxmi; Hernandez, Alexei; Apostol, George; Gao, Yiyang; Llosa, Nicolas; Housseau, Franck; Pardoll, Drew; Jaffee, Elizabeth M; Anders, Robert; Le, Dung T

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly

从十年免疫检查点抑制剂治疗中汲取的经验教训:好的、坏的和丑陋的

Adashek, Jacob J; Moran, Jillian A; Le, Dung T; Kurzrock, Razelle

A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages

一项针对转移性胰腺腺癌的 CXCR4 拮抗剂和 PD1 抑制剂的 2 期试验表明,这些药物可以募集 T 细胞,但也会募集免疫抑制性巨噬细胞。

Bever, Katherine M; Shin, Sarah M; Durham, Jennifer N; Qi, Hanfei; Hernandez, Alexei; Coyne, Erin M; Gross, Nicole E; Charmsaz, Soren; Suresh Babu, Jayalaxmi; Vargas Carvajal, Diana Carolina; Verma, Rohan; Sun, Yanyi; Zhang, Zhehao; Yuan, Xuan; Cannon, Courtney D; Hughes, Sarah N; Mitchell, Sarah; Figlewski, Madeline; Leatherman, James M; Wang, Hao; Anders, Robert A; Jaffee, Elizabeth M; Le, Dung T; Ho, Won Jin

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

urelumab(一种抗CD137激动剂单克隆抗体)联合西妥昔单抗或纳武利尤单抗治疗晚期实体瘤患者的最终结果

Khushalani, Nikhil I; Ott, Patrick A; Ferris, Robert L; Cascone, Tina; Schadendorf, Dirk; Le, Dung T; Sharma, Manish R; Barlesi, Fabrice; Sharfman, William; Luke, Jason J; Melero, Ignacio; Lathers, Deanne; Neely, Jaclyn; Suryawanshi, Satyendra; Sanyal, Abanti; Holloway, James L; Suryawanshi, Rasika; Ely, Scott; Segal, Neil H

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

在既往接受过治疗的胰腺腺癌患者中,使用纳武利尤单抗单药治疗或联合伊匹木单抗(可联合或不联合考比替尼)治疗(CheckMate 032)

Callahan, Margaret; Amin, Asim; Kaye, Frederic J; Morse, Michael A; Taylor, Matthew H; Peltola, Katriina J; Sharma, Padmanee; O'Reilly, Eileen M; Meadows Shropshire, Stephanie; O'Brien, Shaun; Tschaika, Marina; Le, Dung T

Converging on a Cure: The Roads to Predictive Immunotherapy

迈向治愈之路:预测性免疫疗法的路径

Stein-O'Brien, Genevieve L; Le, Dung T; Jaffee, Elizabeth M; Fertig, Elana J; Zaidi, Neeha

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

一项针对可切除胰腺腺癌患者的新辅助和辅助抗肿瘤疫苗单药或联合PD-1拮抗剂和CD137激动剂抗体的平台试验

Heumann, Thatcher; Judkins, Carol; Li, Keyu; Lim, Su Jin; Hoare, Jessica; Parkinson, Rose; Cao, Haihui; Zhang, Tengyi; Gai, Jessica; Celiker, Betul; Zhu, Qingfeng; McPhaul, Thomas; Durham, Jennifer; Purtell, Katrina; Klein, Rachel; Laheru, Daniel; De Jesus-Acosta, Ana; Le, Dung T; Narang, Amol; Anders, Robert; Burkhart, Richard; Burns, William; Soares, Kevin; Wolfgang, Christopher; Thompson, Elizabeth; Jaffee, Elizabeth; Wang, Hao; He, Jin; Zheng, Lei